Lexaria Bioscience Corp.
Close on Oct 19, 2026
- Market cap
- $64.50M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Lexaria Bioscience has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Lexaria Bioscience filed with the SEC
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Lexaria Releases Strategic Letter from the Outgoing CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Positive Interim Body Weight Results from Lexaria’s Diabetes Animal Study
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide
Regulation FD disclosure · EX-99.1 to Form 8-K
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Other events · EX-99 to Form 8-K
Lexaria Granted Two New Patents in Canada
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
Other events · EX-99.1 to Form 8-K
Below I will try to recap our progress of 2022 and indicate why I expect 2023 to be our best year ever. (All dates within this letter refer to calendar periods, not fiscal periods.)
Regulation FD disclosure · EX-99.1 to Form 8-K
Lexaria’s Human Clinical Hypertension Study a Success
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ZACKS INVESTMENT RESEARCH REPORT UPDATE
Regulation FD disclosure · EX-99.1 to Form 8-K
Lexaria Provides Annual Letter From the CEO
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K